These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structural Properties of Potential Synthetic Vaccine Adjuvants - TLR Agonists. Honegr J; Soukup O; Doležal R; Malinak D; Penhaker M; Prymula R; Kuca K Curr Med Chem; 2015; 22(29):3306-25. PubMed ID: 26295466 [TBL] [Abstract][Full Text] [Related]
5. Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague. van der Laan JW Expert Rev Vaccines; 2005 Feb; 4(1):15-8. PubMed ID: 15757468 [No Abstract] [Full Text] [Related]
6. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Skwarczynski M; Toth I Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338 [TBL] [Abstract][Full Text] [Related]
7. Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics. Gupta S; Termini JM; Kanagavelu S; Stone GW Immunol Res; 2013 Dec; 57(1-3):303-10. PubMed ID: 24198065 [TBL] [Abstract][Full Text] [Related]
8. Self-Assembly as a Molecular Strategy to Improve Immunotherapy. Froimchuk E; Carey ST; Edwards C; Jewell CM Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649 [TBL] [Abstract][Full Text] [Related]
9. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129 [TBL] [Abstract][Full Text] [Related]
10. Selection of potent immunological adjuvants for vaccine construction. McElrath MJ Semin Cancer Biol; 1995 Dec; 6(6):375-85. PubMed ID: 8938276 [TBL] [Abstract][Full Text] [Related]
14. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Olive C; Toth I; Jackson D Mini Rev Med Chem; 2001 Nov; 1(4):429-38. PubMed ID: 12369968 [TBL] [Abstract][Full Text] [Related]
15. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764 [TBL] [Abstract][Full Text] [Related]
16. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy]. Kobiyama K; Ishii KJ Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159 [TBL] [Abstract][Full Text] [Related]
17. Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine. Ahmed KK; Geary SM; Salem AK J Pharm Sci; 2016 Mar; 105(3):1173-9. PubMed ID: 26886334 [TBL] [Abstract][Full Text] [Related]
18. Strategies for designing an immunocontraceptive vaccine based on zona pellucida synthetic peptides and recombinant antigen. Kaul R; Afzalpurkar A; Gupta SK J Reprod Fertil Suppl; 1996; 50():127-34. PubMed ID: 8984175 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT; Ott GS; Van Nest G Mol Med Today; 1997 Feb; 3(2):69-75. PubMed ID: 9060004 [TBL] [Abstract][Full Text] [Related]
20. New and safe "oral" live vaccines based on lactobacillus. Claassen E; Van Winsen R; Posno M; Boersma WJ Adv Exp Med Biol; 1995; 371B():1553-8. PubMed ID: 7502855 [No Abstract] [Full Text] [Related] [Next] [New Search]